Lupin receives U.S. approval for another drug

Thursday, 31 July 2008, 07:00 Hrs
Printer Print Email Email
New Delhi: Drug major Lupin announced Thursday that its U.S. subsidiary, Lupin Pharmaceuticals (LPI) has received final approval for the company's Abbreviated New Drug Application (ANDA) for divalproex sodium delayed-release tablets from the U.S. Food and Drug Administration (FDA).

The tablets will be available in 125 mg, 250 mg and 500 mg variants. Commercial shipments have commenced, the company said in a regulatory statement Thursday.

With the approval of this tablet the cumulative ANDA approvals of the company stand at 31 with 34 pending approval from the FDA.
Sources: IANS
SPOTLIGHT
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..